Skip to main content

HubXchange

HubXChange logo

Antibody Therapeutics Xchange - Boston - 2026

Page Banner 1

    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Spotlight Presentation: Accelerating Antibody and Biologic Workflows with Chemically Aware Macromolecule Registration
    Spotlight Presentation: Accelerating Antibody and Biologic Workflows with Chemically Aware Macromolecule Registration
    Track antibody and ADC programs by leveraging CDD Vault’s chemically aware macromolecule capabilitie ...
    James White
    James White, Collaborative Communications - Collaborative Drug Discovery (CDD)
  2. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Developing potent and safe cytotoxins to reduce severe side-effects
    How can we effectively identify the optimal payload–linker combinations to enhance the efficacy and ...
    Victor Goldmacher
    Victor Goldmacher, Chief Scientific Officer - ImmuVia
  3. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Understanding the biology in both tumor (site of efficacy) and normal (sites of potential dose limiting toxicity), & understanding how to tailor the linker to that biology [Topic TBC]
    Candida Cristina Quarta
    Candida Cristina Quarta, Executive Director - Alexion Pharmaceuticals
  4. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Poster Presentation: Development of Dual-Payload Antibody Drug Conjugates
  5. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Tackling the challenge of enhancing cytotoxic payload potency while reducing off-target toxicity in ADCs
  6. Target Selection & Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Integrating target biology and mechanism of action to minimize on-target adverse effects in healthy tissues
    How can we address the challenge of candidate antigens being expressed in both diseased and healthy ...
    Lily Pao
    Lily Pao, Senior Director, Biologics Discovery - Johnson & Johnson
  7. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Reducing resistance of cancer cells to ADC payloads: Biomarker discovery & approaches to tackle drug resistance
    What cellular pathways are responsible for the altered intracellular trafficking or limited lysosoma ...
    Matthew Sung
    Matthew Sung, Director, ADC Biology & Development - AstraZeneca
  8. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Optimizing linkers and conjugation technologies to reduce ADC toxicities
    Marica Speranza
    Marica Speranza, Senior Scientific Director - GSK
  9. Formats & Scaffolds
    • Formats & Scaffolds
    Addressing engineering challenges with bispecific and immunocytokine drugs
  10. Formats & Scaffolds
    • Formats & Scaffolds
    Poster Presentation:
  11. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Balancing linker stability to ensure controlled payload release without compromising ADC efficacy
  12. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Poster Presentation: Optimizing Linker Design for ADCs: CRO Expertise in Stability, Selectivity, and Payload Release
  13. Target Selection & Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Enhancing antigen-specific binding affinity for improved clinical efficacy
  14. Bi/Multispecifics
    • Bi/Multispecifics
    Technologies accelerating engineering into advanced modalities
  15. Lead Identification & Optimization
    • Lead Identification & Optimization
    Leveraging AI and early structural insights to power rational antibody lead design and optimization [Topic TBC]
    Anthony Sandrasagra
    Anthony Sandrasagra, Chief Scientific Officer - Alevian Inc.
  16. Formats & Scaffolds
    • Formats & Scaffolds
    Careful selection of building block properties and compatibility essential to boost overall success of multispecifics
    What is the minimum of sdAb architecture we have to try? How to efficiently link the screening of bi ...
    Tao Wang
    Tao Wang, VP of Product Discovery and Boston Site Head - Crossbow Therapeutics
  17. Lead Identification & Optimization
    • Lead Identification & Optimization
    Advancing biologics discovery and building better medicines
  18. Target Selection & Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Overcoming membrane protein complexes using display technologies
    Lalit Kumar
    Lalit Kumar, Director - Beam Therapeutics
  19. Lead Identification & Optimization
    • Lead Identification & Optimization
    Poster Presentation: Rapid Lead Generation with the Pioneer Antibody Discovery Platform [Topic TBC]

    Bio-Rad

  20. Bi/Multispecifics
    • Bi/Multispecifics
    Poster Presentation: Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D
  21. Target Selection & Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Poster Presentation:
  22. Formats & Scaffolds
    • Formats & Scaffolds
    Challenges of using single domain antibodies as new modalities of multifunctional biologics
    Hongjie Pan
    Hongjie Pan, Director of Antibody Discovery - Leveragen
  23. Bi/Multispecifics
    • Bi/Multispecifics
    Engineering the optimal immune synapse through synthetic design to surpass the endogenous immune response
    Why is reliance on the endogenous immune recognition system (TCE + MHC + antigen) insufficient for e ...
    John Mumm
    John Mumm, CEO & Co-Founder - Deka BioSciences
  24. Lead Identification & Optimization
    • Lead Identification & Optimization
    Balancing speed and quality in antibody lead identification: Can emerging technologies deliver both?
    Rachel Liberatore
    Rachel Liberatore, President & Chief Scientific Officer - RenBio
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Spotlight Presentation: Engineering Unique Properties in Next-Gen Antibody Therapies [Topic TBC]
    Spotlight Presentation: Engineering Unique Properties in Next-Gen Antibody Therapies [Topic TBC]
  26. Bi/Multispecifics
    • Bi/Multispecifics
    Advances and challenges in developing multispecific antibodies
    Xingfeng Bao
    Xingfeng Bao, VP of Biology - GV20 Therapeutics
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Drinks-Canape Reception
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Afternoon Refreshments
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Networking Lunch
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Morning Refreshments
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Opening Address & Keynote Presentation: The Truth About Antibodies and Polyspecificity [Topic TBC]
    Opening Address & Keynote Presentation: The Truth About Antibodies and Polyspecificity [Topic TBC]
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Registration
Search